"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1999 | 4 | 0 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 2 | 2 | 4 |
| 2003 | 2 | 0 | 2 |
| 2004 | 5 | 1 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 7 | 1 | 8 |
| 2007 | 3 | 4 | 7 |
| 2008 | 11 | 2 | 13 |
| 2009 | 2 | 3 | 5 |
| 2010 | 4 | 2 | 6 |
| 2011 | 3 | 3 | 6 |
| 2012 | 1 | 2 | 3 |
| 2013 | 5 | 3 | 8 |
| 2014 | 3 | 4 | 7 |
| 2015 | 6 | 3 | 9 |
| 2016 | 1 | 2 | 3 |
| 2017 | 4 | 2 | 6 |
| 2018 | 1 | 6 | 7 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 7 | 8 |
| 2021 | 4 | 5 | 9 |
| 2022 | 1 | 4 | 5 |
| 2023 | 1 | 0 | 1 |
| 2024 | 3 | 4 | 7 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clin Cancer Res. 2025 Mar 17; 31(6):975-982.
-
The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States. J Med Econ. 2025 Dec; 28(1):335-345.
-
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025 Mar-Apr; 75(2):141-167.
-
Palbociclib plus aromatase inhibitors in patients with metastatic breast cancer and cardiovascular diseases: real-world effectiveness. Oncologist. 2024 Dec 06; 29(12):1032-1043.
-
Real-world quality-of-life of patients with HR+/HER2-?advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat. 2025 Feb; 209(3):613-627.
-
Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024 Nov 22; 79(5):1258-1261.
-
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024 Nov; 19(6):879-892.
-
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct; 8:e2400477.
-
Birth outcomes following bictegravir exposure during pregnancy. AIDS. 2025 Mar 15; 39(4):381-386.
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.